Major VA study to test psilocybin for depression and PTSD
The Department of Veterans Affairs is launching a major clinical trial to study whether psilocybin, the active compound in psychedelic mushrooms, can effectively treat depression and post-traumatic stress disorder in veterans. The study, called the Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression or PIVOT, will enroll at least 240 veterans across five VA medical centers and run through June 2031. VA Secretary Doug Collins announced the initiative as part of the department's effort to evaluate new treatment options for veterans whose mental health conditions have not responded to conventional therapies.
This research comes at a critical time for veterans struggling with treatment-resistant mental health conditions. Major depressive disorder and PTSD remain among the most common and debilitating conditions affecting veterans, often proving difficult to treat with standard medications and therapy alone. The VA currently offers evidence-based treatments including various antidepressants, cognitive behavioral therapy, and other established interventions, but a significant number of veterans continue to experience severe symptoms despite these options. The PIVOT study represents the VA's most ambitious effort yet to explore psychedelic-assisted therapy as a potential alternative for those who have exhausted traditional treatment pathways.
The study will specifically enroll veterans diagnosed with major depressive disorder who have not responded to current treatments, including some participants who also have PTSD diagnoses. Veterans will participate at one of five locations: the Birmingham VA Health Care System and Tuscaloosa VA Medical Center in Alabama, the VA Portland Health Care System in Oregon, Cpl. Michael Crescenz VA Medical Center in Philadelphia, and VA Puget Sound Health Care System in Seattle. The double-blind, randomized trial means neither participants nor researchers will initially know who receives actual psilocybin versus a placebo, ensuring the most scientifically rigorous results possible.
Participants will receive one dose of pharmaceutical-grade psilocybin or placebo along with therapeutic support, followed by a second dose one month later. Veterans will be evaluated two to four weeks after each session and again six months following their participation, allowing researchers to assess both immediate and longer-term effects on depression levels, side effects, and overall treatment response. The controlled clinical setting and pharmaceutical-grade substances distinguish this research from any form of self-medication, which VA officials strongly caution against.
The PIVOT study builds on promising preliminary research, including a recent Ohio State University study of 12 veterans with severe PTSD. In that smaller trial, 75 percent of participants no longer met clinical criteria for PTSD after receiving synthetic psilocybin with psychotherapy, with no serious adverse effects reported. This research follows an executive order signed by President Trump in April directing federal agencies to accelerate review of psychedelic therapies for mental health conditions and increase coordination between the FDA, Department of Health and Human Services, and VA on psychedelic research.
For disabled veterans living with treatment-resistant depression or PTSD, this study represents a potential pathway to relief when other options have failed. The VA currently has staff involved in 20 clinical trials focused on psychedelic treatments, including research on MDMA and LSD, signaling a broader shift in how the department approaches mental health innovation. While these treatments remain experimental and not yet approved for general use, the scale and rigor of the PIVOT study could eventually expand the toolkit available to veterans struggling with severe mental health conditions.
Veterans interested in participating should contact the VA medical centers hosting the trial to learn about specific enrollment criteria and timelines. In the meantime, VA officials emphasize that veterans should continue using proven, evidence-based treatments currently available at VA facilities and avoid self-medicating with unprescribed substances. Those experiencing treatment-resistant depression or PTSD should speak with their VA mental health provider about all available options and whether participation in clinical research might be appropriate for their situation.